Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaFRA:O6PA 58 Current Ratio is 2.45 as of Mar. 2026, which is 20% above its 10-year median of 2.05. GuruFocus rates FRA:O6PA with a GF Score™ of 58/100. The stock has 10 warning signs investors should review. Among 998 Drug Manufacturers companies, Orchid Pharma ranks better than 58.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Orchid Pharma's current ratio for the quarter that ended in Mar. 2026 was 2.45.
Orchid Pharma has a current ratio of 2.45. It generally indicates good short-term financial strength.
The historical rank and industry rank for Orchid Pharma's Current Ratio or its related term are showing as below:
FRA:O6PA'
s Current Ratio Range Over the Past 10 Years
Min: 0.33 Med: 2.05 Max: 3.87
Current: 2.45
During the past 13 years, Orchid Pharma's highest Current Ratio was 3.87. The lowest was 0.33. And the median was 2.05.
FRA:O6PA's Current Ratio is ranked better than 58.92% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:O6PA: 2.45
Orchid Pharma (FRA:O6PA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Orchid Pharma Current Ratio Related Terms
Orchid Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (FRA:O6PA) has a Current Ratio of 2.45 as of Mar. 2026. This is 20% above median its historical median of 2.05. Over the past decade, Orchid Pharma's Current Ratio has ranged from 0.33 to 3.87. According to the industry distribution chart, Orchid Pharma ranks #410 out of 998 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is Orchid Pharma's Current Ratio too high?
Orchid Pharma's current Current Ratio of 2.45 is 20% above median its 10-year median of 2.05. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 3.87. The Drug Manufacturers industry median Current Ratio is 2.00. Orchid Pharma's value of 2.45 is 22.5% above this industry median. Based on the distribution chart, Orchid Pharma ranks #410 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orchid Pharma has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #410 out of 998 companies for Current Ratio. This puts Orchid Pharma in the upper half of its industry. The industry median Current Ratio is 2.00. Orchid Pharma's value of 2.45 is 22.5% above this benchmark. Historically, Orchid Pharma's own Current Ratio has ranged from 0.33 to 3.87 over the past decade. While the company's 10-year median is 2.05 vs. the industry median of 2.00, Orchid Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Current Ratio of 2.45 is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Current Ratio is 2.45, which is 20% above median its own 10-year median of 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (FRA:O6PA) has a current Current Ratio of 2.45. The current Current Ratio is 2.45, which is 20% above median its 10-year median of 2.05 and 22.5% above the Drug Manufacturers industry median of 2.00. Orchid Pharma's overall GF Score™ is 58/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Orchid Pharma (FRA:O6PA), the current Current Ratio is 2.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O6PA has been successfully added to your 
